AI-Powered ISM0900: A New Oral Breakthrough in Lowering Lipoprotein(a) for Heart Health
Insilico Medicine has nominated ISM0900, an AI-designed oral small molecule inhibitor of lipoprotein(a), as a preclinical candidate. Lp(a) is an independent risk factor for cardiovascular disease affecting ~20% of the global population, with no approved therapies yet. This oral therapy could offer a convenient new option for patients.